Macrogenics Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
3.39
0.09
(2.73%)
Volume:
807,687
52 week range:
3.14 - 21.88
Market Cap:
212.628M
Company Description:
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer. The company also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4.